Arcturus Therapeutics is trading 6.2% down now at $14.85, with no clear company-specific catalyst identified for the September 8, 2026 decline.
- The company is scheduled to participate in a Wells Fargo healthcare conference at 2:15 p.m. ET.
- Available coverage does not link the conference to the selloff.
- Broader markets are weaker, but major-index moves do not fully explain the decline.